{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:52Z","timestamp":1790409232258,"version":"4.1.0"},"reference-count":24,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed\/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus &amp;lt;CR. Persistent MRD in the 10\u22126 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed\/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion.<\/jats:p>\n                    <jats:p>See related commentary by Landgren and Kazandjian, p. 346 .<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 337<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0044","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:43:35Z","timestamp":1690206215000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"first","affiliation":[{"name":"1Clinica Universidad de Navarra (CUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Pamplona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6092-1891","authenticated-orcid":false,"given":"Irene","family":"Manrique","sequence":"additional","affiliation":[{"name":"1Clinica Universidad de Navarra (CUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Pamplona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-6790","authenticated-orcid":false,"given":"Julie","family":"Rytlewski","sequence":"additional","affiliation":[{"name":"2Bristol Myers Squibb, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-8784","authenticated-orcid":false,"given":"Timothy","family":"Campbell","sequence":"additional","affiliation":[{"name":"3Bristol Myers Squibb, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0020-6133","authenticated-orcid":false,"given":"Christian C.","family":"Kazanecki","sequence":"additional","affiliation":[{"name":"2Bristol Myers Squibb, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2658-0958","authenticated-orcid":false,"given":"Nathan","family":"Martin","sequence":"additional","affiliation":[{"name":"2Bristol Myers Squibb, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"4Myeloma, Waldenstr\u00f6m's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jes\u00fas G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"5Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"6Emory School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[{"name":"7Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"8Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"9Centre Hospitalier Universitaire de Nantes, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"1Clinica Universidad de Navarra (CUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16\/12\/00369, Pamplona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"10The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8337-9123","authenticated-orcid":false,"given":"Shari M.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"2Bristol Myers Squibb, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2025112416581842500_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/hematology.2022000396","article-title":"Cellular therapy for multiple myeloma: what's now and what's next","volume":"2022","author":"Rodriguez-Otero","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"2025112416581842500_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2025112416581842500_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025112416581842500_bib4","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416581842500_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112416581842500_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from CARTITUDE-1: Phase 1b\/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"2025112416581842500_bib7","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"2025112416581842500_bib8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"2025112416581842500_bib9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025112416581842500_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025112416581842500_bib11","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/cancers13194924","article-title":"Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma","volume":"13","author":"Puig","year":"2021","journal-title":"Cancers"},{"key":"2025112416581842500_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416581842500_bib13","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"2025112416581842500_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112416581842500_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"2025112416581842500_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bjh.18249","article-title":"Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma","volume":"198","author":"B\u00f6ckle","year":"2022","journal-title":"Br J Haematol"},{"key":"2025112416581842500_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025112416581842500_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"2025112416581842500_bib19","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025112416581842500_bib20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2021012319","article-title":"Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change?","volume":"138","author":"Jim\u00e9nez-Ubieto","year":"2021","journal-title":"Blood"},{"key":"2025112416581842500_bib21","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1182\/blood-2022-159141","article-title":"Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1","volume":"140","author":"Munshi","year":"2022","journal-title":"Blood"},{"key":"2025112416581842500_bib22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood-2022-167382","article-title":"Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow","volume":"140","author":"Notarfranchi","year":"2022","journal-title":"Blood"},{"key":"2025112416581842500_bib23","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"key":"2025112416581842500_bib24","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0044\/3348952\/bcd-23-0044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/5\/365\/3408406\/365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/4\/5\/365\/3408406\/365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:58:22Z","timestamp":1764021502000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/4\/5\/365\/728660\/Time-Dependent-Prognostic-Value-of-Serological-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,21]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0044","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.25062070.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062073.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062076.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698514","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024995","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025001","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062064","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024995.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024992.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071496","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024989.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062067","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062079","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024998.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062064.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071493","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071499.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024998","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071508.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071493.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071496.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062070","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062082","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025007","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062067.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024989","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025001.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062079.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071502.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071505.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025007.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025004.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062082.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.30698517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062073","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27024992","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27025004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24071511.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6816228.v3","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6816228","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6816228.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6816228.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}